Short Interest In Synageva BioPharma Drops 13.6%

The most recent short interest data has been released by the NASDAQ for the 12/13/2013 settlement date, which shows a 303,515 share decrease in total short interest for Synageva BioPharma Corp ( GEVA), to 1,923,538, a decrease of 13.63% since 11/29/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for GEVA at the 12/13/2013 settlement increased to 144,484, as compared to 90,213 at the 11/29/2013 report. That brought "days to cover" down to 13.31, a 46.07% decrease from the 24.69 days to cover calculated at the previous short interest data release.

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

The below chart shows the historical "days to cover" for GEVA at previous short interest release dates:

Loading+chart++2013+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where GEVA had been shorted as a hedge.

The chart below shows the one year performance of GEVA shares, versus its 200 day moving average. Looking at this chart, GEVA's low point in its 52 week range is $38.58 per share, with $70.50 as the 52 week high point — that compares with a last trade of $66.06.

Synageva BioPharma Corp Chart

According to the ETF Finder at ETF Channel, GEVA makes up 1.36% of the SPDR S&P Biotech ETF (XBI) which is up by about 0.6% on the day Thursday.

In afternoon trading Thursday, GEVA was trading flat on the day.

If you liked this article you might like

The Nominees for Best Biopharma CEO of 2015 Are...

The Nominees for Best Biopharma CEO of 2015 Are...

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

New Lifetime High Today: Synageva BioPharma (GEVA)

New Lifetime High Today: Synageva BioPharma (GEVA)

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years